CMA proposes Aspen pay-for-delay settlement

The UK’s competition authority has provisionally accepted a £10.1 million settlement from Aspen over an agreement that prevented the entry of a competing version of the drug fludrocortisone.


Get unlimited access to all Global Competition Review content